Form 4 for LRMR Larimar Therapeutics, Inc.
Accepted 2023-05-18 00:00:00 ET · period of report 2023-05-17 · accession 0001062993-23-011546 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-18 | 2023-05-17 | LRMR | BEN-MAIMON CAROLE | Pres, CEO, Dir | P - Purchase | $3.71 | +5,000 | 266.8K | +2% | +$18.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-17 | P | A | 5,000 | $3.71 | 266,829 | D | — | — |